ARVN
Price
$12.59
Change
+$0.17 (+1.37%)
Updated
Nov 28 closing price
Capitalization
808.26M
92 days until earnings call
Intraday BUY SELL Signals
SNDX
Price
$19.82
Change
-$0.05 (-0.25%)
Updated
Nov 28 closing price
Capitalization
1.72B
99 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARVN vs SNDX

Header iconARVN vs SNDX Comparison
Open Charts ARVN vs SNDXBanner chart's image
Arvinas
Price$12.59
Change+$0.17 (+1.37%)
Volume$631.24K
Capitalization808.26M
Syndax Pharmaceuticals
Price$19.82
Change-$0.05 (-0.25%)
Volume$852.29K
Capitalization1.72B
ARVN vs SNDX Comparison Chart in %
ARVN
Daily Signal:
Gain/Loss:
SNDX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARVN vs. SNDX commentary
Nov 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a StrongBuy and SNDX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 30, 2025
Stock price -- (ARVN: $12.59 vs. SNDX: $19.82)
Brand notoriety: ARVN and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 24% vs. SNDX: 28%
Market capitalization -- ARVN: $808.26M vs. SNDX: $1.72B
ARVN [@Biotechnology] is valued at $808.26M. SNDX’s [@Biotechnology] market capitalization is $1.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 1 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • ARVN’s FA Score: 1 green, 4 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARVN and SNDX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 5 TA indicator(s) are bullish while SNDX’s TA Score has 6 bullish TA indicator(s).

  • ARVN’s TA Score: 5 bullish, 4 bearish.
  • SNDX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than ARVN.

Price Growth

ARVN (@Biotechnology) experienced а +9.24% price change this week, while SNDX (@Biotechnology) price change was +13.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.92%. For the same industry, the average monthly price growth was +1.16%, and the average quarterly price growth was +72.91%.

Reported Earning Dates

ARVN is expected to report earnings on Mar 02, 2026.

SNDX is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+6.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.72B) has a higher market cap than ARVN($808M). SNDX YTD gains are higher at: 49.924 vs. ARVN (-34.351). ARVN has higher annual earnings (EBITDA): -112.6M vs. SNDX (-314.25M). ARVN has more cash in the bank: 861M vs. SNDX (469M). SNDX has less debt than ARVN: SNDX (1.68M) vs ARVN (9.9M). ARVN has higher revenues than SNDX: ARVN (373M) vs SNDX (77.9M).
ARVNSNDXARVN / SNDX
Capitalization808M1.72B47%
EBITDA-112.6M-314.25M36%
Gain YTD-34.35149.924-69%
P/E RatioN/AN/A-
Revenue373M77.9M479%
Total Cash861M469M184%
Total Debt9.9M1.68M591%
FUNDAMENTALS RATINGS
ARVN vs SNDX: Fundamental Ratings
ARVN
SNDX
OUTLOOK RATING
1..100
4837
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
91
Overvalued
PROFIT vs RISK RATING
1..100
10087
SMR RATING
1..100
8898
PRICE GROWTH RATING
1..100
3837
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (15) in the Biotechnology industry is significantly better than the same rating for SNDX (91). This means that ARVN’s stock grew significantly faster than SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as ARVN (100). This means that SNDX’s stock grew similarly to ARVN’s over the last 12 months.

ARVN's SMR Rating (88) in the Biotechnology industry is in the same range as SNDX (98). This means that ARVN’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Price Growth Rating (37) in the Biotechnology industry is in the same range as ARVN (38). This means that SNDX’s stock grew similarly to ARVN’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for ARVN (100). This means that SNDX’s stock grew significantly faster than ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNSNDX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 12 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ARVN
Daily Signal:
Gain/Loss:
SNDX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BLYRX38.970.30
+0.78%
American Beacon Man Lg Cp Growth R6
VCDAX202.321.36
+0.68%
Vanguard Consumer Discretionary Idx Adm
IHSIX25.550.16
+0.63%
Hartford Small Company I
CSQCX9.300.02
+0.22%
Calvert Global Small-Cap Equity C
DIFEX12.55N/A
N/A
MFS Diversified Income R2

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+1.33%
AXON - ARVN
46%
Loosely correlated
+1.31%
VCYT - ARVN
46%
Loosely correlated
-0.78%
ERAS - ARVN
40%
Loosely correlated
+1.28%
ATXS - ARVN
40%
Loosely correlated
+0.40%
SRPT - ARVN
40%
Loosely correlated
+1.86%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-0.25%
REPL - SNDX
51%
Loosely correlated
-0.60%
KURA - SNDX
50%
Loosely correlated
+1.25%
XENE - SNDX
45%
Loosely correlated
+0.52%
IDYA - SNDX
45%
Loosely correlated
-0.72%
VCYT - SNDX
45%
Loosely correlated
-0.78%
More